SRR10900552
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.400
- MYC_TARGETS_V1+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- CHOLESTEROL_HOMEOSTASIS+0.200
- DNA_REPAIR+0.200
- FATTY_ACID_METABOLISM+0.200
- HEME_METABOLISM+0.200
- MTORC1_SIGNALING+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- PROTEIN_SECRETION+0.200
Top 10 suppressed
- ANGIOGENESIS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- G2M_CHECKPOINT-0.400
- ALLOGRAFT_REJECTION-0.300
- COMPLEMENT-0.300
- E2F_TARGETS-0.300
- IL2_STAT5_SIGNALING-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013506 | — | cohortA2 | 0.864 |
| 2 | TCGA-A8-A06Y-01A-21R-A00Z-07 | — | B | 0.848 |
| 3 | X08d41e55.6d66.4e03.9dc3.3743f3da0453 | — | cohortA2 | 0.842 |
| 4 | TCGA-CV-A6JY-01A-11R-A31N-07 | — | — | 0.819 |
| 5 | BS_VJVDJABP | Embryonal tumors | — | 0.818 |
| 6 | ULC1533T_S61 | — | cohortA2 | 0.816 |
| 7 | BS_K74PZET7 | Med | Medulloblastoma | 0.810 |
| 8 | MDT-AP-2588 | Med | Medulloblastoma | 0.808 |
| 9 | 37b95452-c6ab-48f9-abd4-521b33596657 | — | — | 0.804 |
| 10 | 103802e1-b3a3-4c55-b094-5011798b6de3 | — | — | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |